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The chromosomal high mobility group box-1 (HMGB1)
protein acts as a proinflammatory cytokine when released
in the extracellular environment by necrotic and inflam-
matory cells. In the present study, we show that HMGB1
exerts proangiogenic effects by inducing MAPK ERK1/2
activation, cell proliferation, and chemotaxis in endothe-
lial cells of different origin. Accordingly, HMGB1 stimu-
lates membrane ruffling and repair of a mechanically
wounded endothelial cell monolayer and causes endothe-
lial cell sprouting in a three-dimensional fibrin gel. In
keeping with its in vitro properties, HMGB1 stimulates
neovascularization when applied in vivo on the top of the
chicken embryo chorioallantoic membrane whose blood
vessels express the HMGB1 receptor for advanced glyca-
tion end products (RAGE). Accordingly, RAGE blockade
by neutralizing Abs inhibits HMGB1-induced neovascu-
larization in vivo and endothelial cell proliferation and
membrane ruffling in vitro. Taken together, the data
identify HMGB1/RAGE interaction as a potent proan-
giogenic stimulus. The Journal of Immunology, 2006,
176: 12–15.
H igh mobility group box-1 (HMGB1)4 is a widely ex-pressed member of the HMGB family of chromo-somal proteins (1). It exerts nuclear functions by in-
teracting with specific DNA structures or after recruitment by
various DNA binding proteins (1).
Recent studies have demonstrated surprising cytokine-like
roles for extracellular HMGB1 (2). Indeed, HMGB1 released
by injured or necrotic cells acts as a signaling molecule, induc-
ing local inflammatory responses (3). Also, HMGB1 is actively
secreted by monocytes stimulated by cytokines and LPS (4). In
turn, extracellular HMGB1 regulates cytokine expression (5, 6)
and promotes inflammatory cell recruitment (3, 5). Moreover,
HMGB1 stimulates the migration of adherent cells, such as fi-
broblasts and smooth muscle cells (7). Thus, extracellular
HMGB1 can be regarded as both a signal of tissue injury and a
mediator of inflammation.
In target cells, extracellularHMGB1 triggers the activation of
themembers of theMAPK pathway ERK1/2. Also, cytoskeleton
reorganization induced by HMGB1 in smooth muscle cells re-
quires the activity of small G proteins (7, 8). These data point to
the presence of cell membrane receptor(s) forHGMB1. Indeed,
binding of HMGB1 to the receptor for advanced glycation end
products (RAGE) induces cell migration, cell invasion, tumor
growth, and metastasis (4, 7, 9). Also, the involvement of the
cell surface heparan-sulfate proteoglycan syndecan-1 and of
TLRs 2 and 4 in cellular activation by HGMB1 has been dem-
onstrated (4, 10, 11).
Angiogenesis, the growth of new blood vessels from pre-ex-
isting ones, plays an important role in various pathological set-
tings, including inflammation, wound repair, and tumor
growth (12). Various cytokines and chemokines exert a proan-
giogenic activity by acting directly on endothelial cells or indi-
rectly by inducing the production of angiogenic growth factors
by inflammatory cells (13–15). Given its cytokine/chemokine-
like features, we investigated the capacity of HMGB1 to mod-
ulate the different steps of the angiogenesis process in vitro and
its proangiogenic activity in vivo. The results identify HMGB1
as a potent angiogenic molecule.
Materials and Methods
Reagents
Eukaryotic recombinant HMGB1 was purified to homogeneity as described
previously (16). The amount of LPS in HMGB1 preparations was equal to 2–3
pg/g protein. At these concentrations, LPS does not exert any effect in the
biological assays used in the present work. Recombinant fibroblast growth fac-
tor-2 (FGF2) was expressed and purified from Escherichia coli cell extract (17).
Neutralizing polyclonal anti-RAGE Ab (AF1179) was from R&D Systems.
Cell cultures
Fetal bovine aortic endothelial GM7373 cells (17) were grown in DMEM con-
taining 10% FCS (Invitrogen Life Technologies). Immortalized BALB/c mu-
rine aortic endothelial (MAE) cells were grown in DMEM (Invitrogen Life
Technologies) added with 10% FCS. Murine lung microvascular endothelial
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cells (1G11 cells) (18) were grown in DMEM supplemented with 1% nones-
sential amino acids and 20% FCS on gelatin-coated dishes.
ERK1/2 phosphorylation
Subconfluent cell cultures were seeded in 24-well plates and incubated for 16 h
at 37°C in serum-free DMEM. Then, cells were treated with HMGB1 without
changing the medium. After 30 min at 37°C, Western blot analysis of the cell
extracts was performed using anti-phospho-ERK1/2 Ab (Santa Cruz Biotech-
nology). Immunocomplexes were visualized using the ECL Western blotting
kit (Amersham Biosciences).
Cell proliferation
GM7373 cells were seeded at 70,000 cells/cm2 in 96-well dishes. After over-
night incubation, cells were treated with HMGB1 in fresh medium containing
0.4% FCS. After 24 h, cells were trypsinized and counted in a Burker chamber.
Endothelial cell sprouting
MAE cell aggregates were prepared on agarose-coated plates and embedded in
fibrin gel (17). Then, culture medium containing HMGB1 was added on the
top of the gel in the presence of 10 g/ml aprotinin. After 48 h, sprouts were
photographed at 40 magnification and quantified by computerized analysis
of the digitalized images (17).
Wounding of endothelial cell monolayer
GM7373 cell monolayers were wounded with a 1.0-mm-wide rubber police-
man and incubated in freshmedium addedwith 0.4%FCS and increasing concen-
trations of HMGB1. After 3 h, the percentage of cells at the edge of the wound
showing cell membrane ruffles was counted under a inverted microscope at400
magnification.After 24h,woundswere photographed, anddenudedwounded area
was quantified by computerized analysis of the digitalized images (17).
Chemotaxis
Cells were seeded at 1.0 106 cells/ml in the upper compartment of a Boyden
chamber containing gelatin-coated polyvinylpyrrolidone-free polycarbonate
filters (5-m pore size; Costar). Increasing concentrations of HMGB1 dis-
solved in DMEM with 1% FCS were placed in the lower compartment. After
4 h of incubation at 37°C, cells migrated to the lower side of the filter were
stained with Diff-Quik (Dade-Behring). Five random fields were counted for
each triplicate sample.
Chicken embryo chorioallantoic membrane (CAM) assay
Alginate beads (5 l) containing vehicle, 300 ng of HMGB1 with or without
100 ng of neutralizing anti-RAGE Ab were prepared as previously described
(19) and placed on top of the CAM of fertilizedWhite Leghorn chicken eggs at
day 11 of incubation. After 72 h, blood vessels converging toward the implant
were counted at 50 magnification. Next, paraffin-embedded longitudinal
CAM sections were processed for light microscopy (H&E) and immunostain-
ing using a monoclonal anti-RAGE Ab (Chemicon International).
Data representation
Data are the mean SD of two to three independent experiments in triplicate.
Statistical analyses were done using Student’s t test.
Results
HMGB1 induces a proangiogenic response in endothelial cells in vitro.
Angiogenesis begins with the degradation of the basement
membrane by activated endothelial cells that will migrate and
proliferate, leading to the formation of solid sprouts into the
stroma. Then, vascular loops are formed and capillary tubes de-
velop (20). In vitro assays have been developed to mimic the
different steps of the angiogenesis process. However, a high de-
gree of heterogeneity exists for endothelial cells from different
sources (21). On this basis, to assess the proangiogenic potential
of HMGB1, the purified eukaryotic recombinant protein was
evaluated for the capacity to induce a proangiogenic response in
different in vitro assays using large-vessel and microvascular en-
dothelial cells of murine and bovine origin.
As shown in Fig. 1A, recombinant HMGB1 causes the
activation of intracellular ERK1/2 signaling in bovine aortic en-
dothelial GM7373 cells in a dose-dependent manner. A similar
effect was observed in murine endothelial MAE cells (data not
shown). Also, HMGB1 induces a significant mitogenic
response in GM7373 cells similar to that exerted by the angio-
genic growth factor FGF2,maximal stimulation being observed
at 25–50 ng/ml HMGB1 (Fig. 1B). The effect was inhibited by
blocking Abs directed against the HMGB1 receptor RAGE but
not by irrelevant IgGs (Fig. 1B).
HMGB1 exerts chemotactic activity for different cells types
of mesodermal origin (7). Accordingly, HMGB1 induces the
migration of GM7373 and murine microvascular 1G11 cells
when tested in a Boyden chamber assay (Fig. 2). The effect was
dose dependent, maximal response being observed at 75 and
150 ng/ml for GM7373 and 1G11 cells, respectively. Also,
HMGB1 stimulates the formation of endothelial cell sprouts
from aggregates of MAE cells embedded in a three-dimensional
fibrin gel, maximal effect being observed at 25 ng/ml of the cy-
tokine (Fig. 3).
Migration of endothelial cells following the mechanical
wounding of the cell monolayer is characterized by cytoskeleton
reorganization and formation of cell membrane ruffles (17). In
keeping with its motogenic activity, HMGB1 stimulates the
formation of membrane ruffles in GM7373 cells at the edge of
the wound (Fig. 4, A and B). This was followed by the more
rapid repair of theHMGB1-treatedmonolayer when compared
with vehicle-treated cells (Fig. 4C). In both assays, the stimula-
tion exerted by HMGB1 was similar to that shown by FGF2.
Again, HMGB1-mediatedmembrane ruffle formation was pre-
vented by blocking anti-RAGE Abs (Fig. 4B).
FIGURE 1. HMGB1 stimulates endothelial cell proliferation. A, GM7373
cells were stimulated for 30 min with increasing concentrations of HMGB1 or
with FGF2 (30 ng/ml). Cell extracts were analyzed by immunoblotting for
ERK1/2 phosphorylation. Uniform loading of the gel was confirmed by immuno-
blotting with anti-tubulin Ab. B, GM7373 cells were counted 24 h after stimula-
tion with FGF2 (30 ng/ml, arrow) or with HMGB1 in the absence (F) or in the
presence of 20 g/ml blocking anti-RAGE Abs (f) or irrelevant IgGs (). Cells
maintained in 0.4% FCS undergo 0.2 cell population doublings in 24 h.
FIGURE 2. HMGB1 induces endothelial cell chemotaxis. GM7373 (F)
and 1G11 (E) cells were assessed for their capacity to migrate in response to
HMGB1 in a Boyden chamber assay. After 4 h, cells that migrated to the lower
side of the filter were counted, and data were expressed as percentage of cells
migrated in the absence of a chemotactic stimulus.
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In conclusion,HMGB1 induces a complex proangiogenic re-
sponse in cultured endothelial cells characterized by activation
of ERK1/2 signaling, cell proliferation, migration, and endothe-
lial cell sprouting.
HMGB1 stimulates neovascularization in vivo
To assess the proangiogenic activity of HMGB1 in vivo,
HMGB1-loaded alginate beads were implanted onto the
chicken embryo CAM at 11 days of development. After 72 h, a
robust angiogenic response was observed around the HMGB1
implants when compared with vehicle-treated embryos (Fig. 5,
a and b). The number of macroscopic blood vessels converging
toward the alginate pellets was equal to 28 7 and 10 7 for
HMGB1 (n 19) and vehicle (n 15) implants, respectively
(p  0.0001). To evaluate the possibility that HMGB1 may
exert an indirect effect on angiogenesis by recruiting a proin-
flammatory infiltrate, we performed histological analysis of
HMGB1-treated CAMs. H&E staining of CAM sections con-
firmed the potent proangiogenic activity of HMGB1 as evi-
denced by numerous blood vessels filled with nucleated avian
erythrocytes (Fig. 5, c and d). A limited mononuclear cell infil-
trate was detectable in the surrounding mesenchyma when
compared with vehicle-treated CAMs (Fig. 5e). This is in keep-
ing with previous observations on FGF2-treated CAMs in
which scattered infiltrating mononuclear cells can be observed
(22), but it differs significantly from the massive mononuclear
cell infiltrate that parallels the angiogenic response elicited in
the same experimental model by the inflammatory cell che-
moattractants osteopontin (22) and IL-8 (M. Presta and D.
Ribatti, unpublished observations).
Finally, immunostaining of CAM sections demonstrated the
expression of the HMGB1 receptor RAGE on the surface of
endothelial cells (Fig. 5, f and g). Accordingly, blocking anti-
RAGE Abs (100 ng/implant) prevented the angiogenic re-
sponse elicited by HMGB1 in five of six embryos tested in
which the number of newly formed macroscopic blood vessels
was reduced to 14  4, similar to vehicle-treated CAMs (see
above). No effect was instead exerted by irrelevant IgGs (27
4 vessels/implant, n  4).
Discussion
In the present work, we demonstrate for the first time that ex-
tracellular HMGB1 induces a proangiogenic phenotype in en-
dothelial cells and triggers a potent angiogenic response in vivo
in the chick embryo CAM.
Similar to proangiogenic growth factors and cytokines,
HMGB1 causes activation of ERK1/2 intracellular signaling
that is paralleled by a significant increase in the rate of growth of
endothelial cells in vitro. Also, HMGB1 induces endothelial
cell chemotaxis and an increase in cell motility in a wounded
endothelial cell monolayer. Accordingly, HMGB1 stimulates
the formation of endothelial cell sprouts in a three-dimensional
fibrin gel. In keeping with its ability to induce a complex proan-
giogenic phenotype in vitro, HMGB1 exerts a robust angio-
genic response when delivered on the top of the chick embryo
CAM. A recent report demonstrating the capacity of HMGB1
to stimulate human endothelial cell migration within collagen
gel (23) further strengthens our observations.
Extracellular HMGB1 interacts with cell surface receptors,
including RAGE (4). HMGB1/RAGE interaction activates
parallel signaling pathways, including ERK1/2 and NF-B acti-
vation (4), both involved in angiogenesis (24, 25). Accordingly,
the ability of RAGE ligands advanced glycation end products to
induce angiogenesis has been demonstrated (26). Thus, it is
conceivable that RAGEmaymediate the proangiogenic activity
of HMGB1. Indeed, our data demonstrate that blocking anti-
RAGE Abs inhibit the capacity of HMGB1 to trigger cell pro-
liferation and membrane ruffling in endothelial GM7373 cells
in vitro and neovascularization in vivo in the chick embryo
CAM whose blood vessels express RAGE. In keeping with this
hypothesis is also the observation that RAGE mediates endo-
thelial cell activation (27), smooth muscle cell migration (7),
and mesoangioblast migration and proliferation triggered by
extracellular HMGB1 (28). In contrast, HMGB1 can interact
with TLRs (4, 10) that play an important role inmediating neo-
vascularization during activation of the innate immune re-
sponse (29). Also, HMGB1 binds syndecan-1, a cell surface
heparan-sulfate proteoglycan whose involvement in angiogen-
esis is well established (30). Thus, the possibility that other re-
ceptors, together with RAGE,may contribute to the angiogenic
activity of HMGB1 cannot be ruled out.
HMGB1 is released by injured or necrotic cells and actively
secreted by activated macrophages (Refs. 1, 2, 4 and references
therein). In turn, extracellularHMGB1 induces the secretion of
proangiogenic cytokines (e.g., TNF- and IL-8) (4). Thus,
HMGB1 may induce angiogenesis by interacting directly with
endothelial cells (as suggested by our observations) and/or by
FIGURE 3. HMGB1 induces endothelial cell sprouting. MAE cell aggre-
gates embedded in fibrin gel were incubated for 48 h in the presence of
HMGB1, photographed at 40 magnification, and sprouting was quantified
by computerized analysis of the digitalized images. Inset, Representative images
of cell aggregates in the presence of vehicle (a) or 25 ng/ml HMGB1 (b).
FIGURE 4. HMGB1 stimulates the repair of a wounded endothelial cell
monolayer.Wounded GM7373 cell monolayers were incubated withHMGB1
in the absence or in the presence of 20 g/ml blocking anti-RAGE Abs (f) or
FGF2 (30 ng/ml) plus 0.4% FCS. After 3 h, migrating cells at the edge of the
wound were photographed (A), and the percentage of cells showing cell mem-
brane ruffles was evaluated (F) (B). After 24 h, the residual denuded area was
quantified by computerized analysis (C). A, Representative images of vehicle-
treated (a) and HMGB1-treated (100 ng/ml) cells (b) at the wound edge (ar-
rows: membrane ruffles).
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stimulating the recruitment and activation of proangiogenic in-
flammatory cells (as indicated for different cytokines (13–15)).
Histological analysis of the chick embryo CAM has shown the
presence of a limited mononuclear cell infiltrate in HMGB1-
treated embryos similar to that found in FGF2-treated CAMs
(22). This suggests that CAM neovascularization is triggered
mainly by a direct interaction of HMGB1 with endothelium
rather than by an indirect effect mediated by activated inflam-
matory cells. This differs from previous data about the indirect,
macrophage-mediated angiogenic response elicited by osteopontin
in the same experimental model (22). Clearly, we cannot rule out
the possibility that monocyte recruitment and activationmay play
a significant role in HMGB1-triggered vascularization under dif-
ferent experimental conditions as well as in acute and chronic in-
flammatory diseases, including neoplasia (23).
The intracellular abundance of HMGB1 and its proinflam-
matory activities suggest that its release/secretion at sites of tis-
sue damage may play an important role during inflammatory/
immune responses (4). Given the importance of neovascular-
ization at the site of injured tissue, where blood flow restoration
is often a necessary prerequisite for mounting an initial immune
response to pathogens and for subsequent initiation of a suc-
cessful repair of wounded tissue (29), the capacity of extracel-
lular HMGB1 to exert a potent angiogenic activity strengthens
the importance of HMGB1 as a cytokine.
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FIGURE 5. HMGB1 stimulates angiogenesis in the chick embryo CAM.
Macroscopic images of CAMs treated with vehicle (a) or 300 ng of HMGB1
(b). Note the robust neovascular response converging toward the HMGB1 im-
plant. Histological analysis (H&E) of CAM sections shows numerous blood
vessels filled with nucleated avian erythrocytes (d, 200 magnification) and
scattered infiltrating mononuclear cells (arrows in e, 400 magnification) in
HMGB1-treated CAMs compared with controls (c). Immunoperoxidase stain-
ing of CAM blood vessels (arrows) using an anti-RAGE mAb (g). The negative
control in which the primary Ab was omitted is shown in f (H&E counterstain-
ing, 400 magnification).
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